These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 23851570

  • 21. Tolerability and safety profile of risperidone in a sample of children and adolescents.
    Margari L, Matera E, Craig F, Petruzzelli MG, Palmieri VO, Pastore A, Margari F.
    Int Clin Psychopharmacol; 2013 Jul; 28(4):177-83. PubMed ID: 23689836
    [Abstract] [Full Text] [Related]

  • 22. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment.
    Masi G, Cosenza A, Mucci M.
    J Child Adolesc Psychopharmacol; 2001 Jul; 11(4):389-94. PubMed ID: 11838821
    [Abstract] [Full Text] [Related]

  • 23. Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study.
    Kim E, Yu KS, Cho JY, Shin YW, Yoo SY, Kim YY, Jang IJ, Shin SG, Kwon JS.
    Hum Psychopharmacol; 2006 Dec; 21(8):519-28. PubMed ID: 16981227
    [Abstract] [Full Text] [Related]

  • 24. CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study.
    Youngster I, Zachor DA, Gabis LV, Bar-Chaim A, Benveniste-Levkovitz P, Britzi M, Soback S, Ziv-Baran T, Berkovitch M.
    Dev Med Child Neurol; 2014 Oct; 56(10):990-4. PubMed ID: 24828442
    [Abstract] [Full Text] [Related]

  • 25. Association of dopamine D2 receptor gene polymorphisms with prolactin levels related to risperidone treatment: A systematic review and meta-analysis.
    Ma L, Xiang Q, Zhou S, Tan Y, Zhang X, Yang T, Xie Q, Mu G, Zhao X, Zhou Y, Li S, Cui Y.
    J Clin Pharm Ther; 2019 Aug; 44(4):543-552. PubMed ID: 31056781
    [Abstract] [Full Text] [Related]

  • 26. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.
    Melkersson KI.
    Hum Psychopharmacol; 2006 Dec; 21(8):529-32. PubMed ID: 17094165
    [Abstract] [Full Text] [Related]

  • 27. Antipsychotic-induced hyperprolactinemia and testosterone levels in boys.
    Roke Y, van Harten PN, Buitelaar JK, Tenback DE, de Rijke YB, Boot AM.
    Horm Res Paediatr; 2012 Dec; 77(4):235-40. PubMed ID: 22538969
    [Abstract] [Full Text] [Related]

  • 28. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
    Yagihashi T, Mizuno M, Chino B, Sato Y, Sakuma K, Takebayashi T, Takao T, Kosaki K.
    Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
    [Abstract] [Full Text] [Related]

  • 29. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
    Bork JA, Rogers T, Wedlund PJ, de Leon J.
    J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802
    [Abstract] [Full Text] [Related]

  • 30. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
    Leon Jd, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ.
    Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
    [Abstract] [Full Text] [Related]

  • 31. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C.
    Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
    [Abstract] [Full Text] [Related]

  • 32. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions.
    Correia CT, Almeida JP, Santos PE, Sequeira AF, Marques CE, Miguel TS, Abreu RL, Oliveira GG, Vicente AM.
    Pharmacogenomics J; 2010 Oct; 10(5):418-30. PubMed ID: 19997080
    [Abstract] [Full Text] [Related]

  • 33. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
    Iwata Y, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Plitman E, Chung JK, Mar W, Gerretsen P, Pollock BG, Mulsant BH, Rajji TK, Mamo DC, Graff-Guerrero A.
    J Clin Psychiatry; 2016 Dec; 77(12):e1557-e1563. PubMed ID: 28086010
    [Abstract] [Full Text] [Related]

  • 34. Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.
    Yasui-Furukori N, Tsuchimine S, Saito M, Nakagami T, Sugawara N, Fujii A, Kaneko S.
    J Clin Psychopharmacol; 2011 Oct; 31(5):633-7. PubMed ID: 21869689
    [Abstract] [Full Text] [Related]

  • 35. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.
    Montalvo I, Ortega L, López X, Solé M, Monseny R, Franch J, Vilella E, Labad J.
    Int Clin Psychopharmacol; 2013 Jan; 28(1):46-9. PubMed ID: 23232756
    [Abstract] [Full Text] [Related]

  • 36. [Clinical pharmacogenetics in the treatment of schizophrenia].
    Saito M, Yasui-Furukori N, Kaneko S.
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Jun; 25(3):129-35. PubMed ID: 16045195
    [Abstract] [Full Text] [Related]

  • 37. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
    Segal M, Avital A, Derevenski A, Berstein S, Sandbank S, Weizman A.
    Int Clin Psychopharmacol; 2007 Jul; 22(4):192-6. PubMed ID: 17519641
    [Abstract] [Full Text] [Related]

  • 38. Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene.
    Mihara K, Kondo T, Suzuki A, Yasui N, Nagashima U, Ono S, Otani K, Kaneko S.
    Psychopharmacology (Berl); 2000 Apr; 149(3):246-50. PubMed ID: 10823405
    [Abstract] [Full Text] [Related]

  • 39. Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia.
    Suzuki Y, Tsuneyama N, Fukui N, Sugai T, Watanabe J, Ono S, Saito M, Someya T.
    J Clin Psychopharmacol; 2013 Jun; 33(3):411-4. PubMed ID: 23609388
    [Abstract] [Full Text] [Related]

  • 40. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders.
    Hellings JA, Zarcone JR, Valdovinos MG, Reese RM, Gaughan E, Schroeder SR.
    J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):885-92. PubMed ID: 16379508
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.